Join us as Dr. Siddharthan presents insights on the role of the ST2/IL-33 pathway in the pathogenesis of COPD
| Estimated time to read:
Tuesday, October 21, 2025 | 2:00 PM-2:45 PM CT | McCormick Place, Learning Theater 3
Exacerbations are still a major challenge in the treatment of COPD
Acute exacerbations frequently result in hospital admission and are associated with lung function decline, prolonged negative effects on quality of life, and an increased risk of mortality.1
Unaddressed progressive airway inflammation is the culprit
Neutrophilic inflammation is the predominant inflammation type in 60%-80% of COPD patients.2 With its central role in pathogenesis, addressing it remains a significant unmet need in COPD treatment.3-5 Eosinophilic inflammation is elevated in 20%-40% of patients with COPD with an estimated 20% of patients having a blood eosinophil count ≥300 cells/µL.6,7
The ST2/IL-33 pathway plays a role in the inflammatory pathogenesis of COPD
Patients with COPD have increased ST2 and IL-33 levels compared to healthy individuals, which have been shown to correlate with exacerbation risk and disease severity in COPD.8,9
The ST2/IL-33 pathway is a novel target in COPD
There is an unmet need to develop treatments targeting underlying disease mechanisms and inflammatory pathways involved in COPD.9,10
COPD=chronic obstructive pulmonary disease; IL=interleukin; NIH=National Institutes of Health; ST2=suppression of tumorigenicity 2.
References: 1. Hurst JR, et al. Eur J Intern Med. 2020;73:1-6. 2. Katsoulis O, et al. Nat Commun. 2024;15(1):5766. 3. Yang H, et al. BMJ Open Respir Res. 2023;10(1):e001597. 4. Barnes PJ. J Allergy Clin Immunol. 2016;138(1):16-27. 5. Lonergan M, et al. Respir Res. 2020;21(1):166. 6. Rabe KF, et al. Am J Respir Crit Care Med. 2023;208(4):395-405. 7. Tashkin DP, Wechsler ME. Int J Chron Obstruct Pulmon Dis. 2018;13:335-349. 8. Joo H, et al. BMC Pulm Med. 2021; 21(1):86. 9. Calderon AA, et al. Eur Respir Rev. 2023;32(167): 220144. 10. Yadav AK, et al. COPD. 2023; 20(1):197-209.
About Dr. Trishul Siddharthan, MD, FCCP, ATSF
Dr. Siddharthan is an Associate Professor of Medicine in the Division of Pulmonary, Critical Care, and Sleep Medicine at the University of Miami Miller School of Medicine, where he serves as the Director of Clinical Research and leads the Center for COPD and Asthma. He has published more than 100 peer-reviewed manuscripts, book chapters, and reviews spanning COPD, asthma and bronchiectasis. His research integrates airway disease, functional imaging, and biomarker discovery with advanced digital health technologies. Dr. Siddharthan has received numerous honors and has been supported by funding from the NIH, the Department of Defense, the American College of Chest Physicians, and industry partners. He is an active mentor to early-career investigators supported by NIH F32 and K-level awards, as well as international trainees globally.
This is a non-CME event and does not qualify for CME, CE, or MOC credit. This event is not part of the official CHEST Annual Meeting 2025 conference sessions. This event is not an endorsement by CHEST and does not reflect the views or opinions of CHEST.
M-US-000282525(v2.0) 09/25
© 2025 Genentech, Inc. All rights reserved.
